Melatonin and menopause: study says the hormone can help

Melatonin and menopause, a match made in heaven? A new study by an international group of researchers finds that menopausal women could benefit from taking doses of the sleep hormone melatonin in order to alleviate some of the troubling symptoms of menopause, some of which can lead to further health complications even after the menopausal transition is over.

Menopause is the name given to the last stage of a woman’s reproductive age when menstruation ceases to occur (in Canada, the average age of onset is 51) and hormonal changes produce symptoms ranging from hot flashes and night sweats to weight gain, mood disruptions and sleep problems. Insomnia, awakenings in the middle of the night and in the early morning are all common complaints associated with menopause.

And while for a majority of women, these problems dissipate once the menopausal transition is over (which can take years — evidence suggests that women experience symptoms for an average of seven years after the onset of perimenopause), for some, the disturbances of menopause can contribute to more long-term health concerns.

But research suggests that the decrease in production of melatonin could be responsible for menopausal sleep-related issues and thus that supplementation with melatonin doses may help not only with sleep but mood and well-being, too.

Melatonin and menopause: levels decrease with age…

“Melatonin levels decrease (especially at nighttime) with age, particularly during the peri-menopausal period,” say the new study’s authors, an international group of researchers from the United States, Canada, India, Germany and Israel. “This observation has led some to speculate that melatonin may play a role in the menopausal transition.”

Melatonin is a central player in the body’s circadian rhythm, which links up the sleep-wake cycle with the natural day/night cycle. Light turns off the production of melatonin in the body, while darkness causes more melatonin to be produced, which signals the body that it’s time to sleep.

Importantly, melatonin secretion affects the entire body, circulating through to all cells, which means that the impact of having lower levels of melatonin, as experienced in menopause, can be far-reaching, potentially effecting a number of physiological functions.

For one, melatonin plays a role in immune system functioning, helping to regulate anti-inflammatory and anti-oxidant responses. “The circadian system controls countless physiological and cell biological functions,” say the authors. “This system exhibits a remarkable complexity.”

To that end, the researchers point to a number of health effects that are a risk to postmenopausal women which studies indicate could be connected to a lack of melatonin, including serious conditions such as depression, fibromyalgia, breast cancer and endometrial cancer. Getting enough melatonin, therefore, through supplements, can help counter the risks of such problems.

“While there is obviously a need for continued research, there are effective behavioural and pharmacological therapies available to treat sleep disturbances at this time in a woman’s life,” say the study’s authors, who suggest that further investigations by randomized controlled studies are “highly desirable” in order to evaluate the efficacy of melatonin-based therapy for peri- and postmenopausal women.

The new study is published in the journal Sleep Science.

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Booking Holdings is “best in class”, this investor says

In an appearance on BNN Bloomberg Market Call on April 8, First Avenue Investment Counsel chief investment officer Brian Madden… [Read More]

21 hours ago

Should you sell your NowVertical stock?

Ventum Capital Markets analyst Robb Goff cut his target on NowVertical Group (NowVertical Group Stock Quote, Chart, News, Analysts, Financials… [Read More]

22 hours ago

This analyst says Constellation Brands is a “Top Pick”

Roth Capital Markets analyst Bill Kirk reiterated his “Top Pick” and “Buy” rating on Constellation Brands (Constellation Brands Stock Quote,… [Read More]

22 hours ago

Here’s why Micron is a great AI play

Micron Technology (Micron Technology Stock Quote, Chart, News, Analysts, Financials NASDAQ:MU) remains an underappreciated AI name, according to Forvest Global… [Read More]

1 day ago

This analyst just slashed his price target on Byrna Technologies

Roth Capital Markets analyst Matt Koranda maintained his “Buy” rating on Byrna Technologies (Byrna Technologies Stock Quote, Chart, News, Analysts,… [Read More]

1 day ago

Beacon raises price target on Firan Technology to $26.00

Beacon Securities analyst Russell Stanley raised his target on Firan Technology Group (Firan Technology Group Stock Quote, Chart, News, Analysts,… [Read More]

1 day ago